Zefit announced on the 17th that it received the Innovation Award in the 'Human Security' category at 'CES 2026', the world's largest IT and electronics exhibition.

This award recognizes the innovation of Zefit's patient-customized zebrafish avatar-based anticancer drug sensitivity evaluation platform 'Onco-FIT', which integrates alternative animal models, artificial intelligence (AI), and robotics technology in the medical field to enhance the efficiency of personalized optimal cancer treatment and contribute to improving patient survival rates.

'Onco-FIT' is a precision medicine service platform that swiftly and accurately verifies the responsiveness of various anticancer drugs using a patient-customized avatar model implanted in zebrafish, based on the patient's tumor tissue or genetic information. This platform is characterized by its ability to predict patient-specific treatment responses in the preclinical stage and assist medical professionals in selecting the optimal anticancer drugs.

With the CES Innovation Award as a catalyst, Zefit is expanding its service disease areas to include rare and genetic diseases and is collaborating with major domestic university hospitals to verify the clinical validity (Proof of Concept, PoC) of patient-customized treatments.

A Zefit representative stated, "The CES Innovation Award is an official recognition of Zefit's technological prowess and global competitiveness," and added, "Following the clinical PoC, we will fully launch the service to present a new paradigm of personalized treatment and lead the global precision medicine market."

Popular News